<DOC>
	<DOCNO>NCT02392416</DOCNO>
	<brief_summary>Treatment hypercholesterolemia base guideline ESC-EAS 2011 ( European Heart Journal ( 2011 ) 32 , 1769-1818 , ESC / EAS Guidelines management dyslipidaemias ) These calculate 10 year risk base SCORE table - Systematic COronary Risk Estimation take account specific parameter patient 's profile .</brief_summary>
	<brief_title>Atorvastatin Study Cardiovascular Disease Risk</brief_title>
	<detailed_description>The European Society Cardiology initiate development new risk calculation system ( SCORE ) use data 12 European population monitoring study ( N = 205.178 ) wide geographic distribution country different cardiovascular risk . The SCORE data contain 3 million man-years observation 7934 fatal cardiovascular event . - patient classify risk category ( Very high-high-medium-low ) - target LDL-C place risk basis appropriate treatment propose - As first option statin monotherapy maximum tolerate dose . - Only case failure therapeutic target LDL-C may use active substance therapeutic class alternative monotherapy combination statin , Because European country exhibit heterogeneity genetics , lifestyle , living standard , health benefit , etc . divide two group , high risk ( country ) low risk ( country ) prepare different table SCORE ( Systematic COronary Risk Estimation ) For Greece , country refinement SCORE trained specialist table adapt Greek population ( Statistical The currently use treatment Greece atorvastatin , obtain 520,000 patient From far study atorvastatin well document reduction various lipid parameter especially LDL-C , main objective treatment . But evidence suggest dosage prove suitable practice patient depend risk class belongs .</detailed_description>
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<criteria>External outpatient monitor externally hospital lipid clinic , hypercholesterolemia , diabetic etc . Male female Eligible age study : 1899 year Patients first diagnosis hypercholesterolemia receive Atorvastatini accord standard clinical practice Established cardiovascular disease interventional noninterventional examination ( coronary angiography , nuclear medicine , echocardiography stress , carotid plaque ultrasound ) , previous myocardial infarction , ACS , coronary revascularization ( PCI , CABG ) , arterial revascularization procedure , ischemic stroke , peripheral arterial disease ( PAD ) Diabetes mellitus ( type 1 type 2 ) one cardiovascular risk factor / target organ damage ( microalbuminuria : 30300 mg / 24 h ) Patients already diagnose hypercholesterolemia unregulated receive Atorvastatini accord standard clinical practice Patients diagnose set original formulation atorvastatin Patients fully understood study protocol sign consent form Patients &lt; 18 year Hypersensitivity atorvastatin excipients Women pregnant breastfeeding Patients fully understood study protocol sign consent form</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>